Detailed price information for Molina Healthcare Inc (MOH-N) from The Globe and Mail including charting and trades.

The latest trading session saw Vertex Pharmaceuticals (VRTX) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex forecasts upbeat 2025 revenue on cystic fibrosis treatments demand Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal — all designed to enhance performance when navigating rugged ...

Johnson leads LIV Golf Singapore presented by Aramco by three shots after a bogey-free 63 in Friday's opening round at Sentosa Golf Club. His 8-under round matches his best single-round LIV Golf ...

Volkswagen’s ultimate enthusiast car, the Golf R, faces something of a win-some, lose-some situation. After 2024 it bid auf wiedersehen to its optional six-speed manual transmission, making a ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...